Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Preferentially rated health-related activities or functions to be used in establishing health planning goals. This may refer specifically to PL93-641.
The obligations and accountability assumed in carrying out actions or ideas on behalf of others.
Success in bringing an effort to the desired end; the degree or level of success attained in some specified area (esp. scholastic) or in general.
Branch of medicine concerned with the prevention and control of disease and disability, and the promotion of physical and mental health of the population on the international, national, state, or municipal level.
Personal satisfaction relative to the work situation.
The concept concerned with all aspects of providing and distributing health services to a patient population.
Techniques used in studying bacteria.
A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.
Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID.
Studies determining the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. For drugs and devices, CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; and DRUG EVALUATION, PRECLINICAL are available.
Facilities which provide nursing supervision and limited medical care to persons who do not require hospitalization.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.
A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed)
A multifunctional pyridoxal phosphate enzyme. In the final step in the biosynthesis of cysteine it catalyzes the cleavage of cystathionine to yield cysteine, ammonia, and 2-ketobutyrate. EC 4.4.1.1.
Chemical groups containing the covalent sulfur bonds -S-. The sulfur atom can be bound to inorganic or organic moieties.
Changes in quantitative and qualitative composition of MICROBIOTA. The changes may lead to altered host microbial interaction or homeostatic imbalance that can contribute to a disease state often with inflammation.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Generally refers to the digestive structures stretching from the MOUTH to ANUS, but does not include the accessory glandular organs (LIVER; BILIARY TRACT; PANCREAS).
The full collection of microbes (bacteria, fungi, virus, etc.) that naturally exist within a particular biological niche such as an organism, soil, a body of water, etc.
The selected form given to a natural tooth when it is reduced by instrumentation to receive a prosthesis (e.g., artificial crown or a retainer for a fixed or removable prosthesis). The selection of the form is guided by clinical circumstances and physical properties of the materials that make up the prosthesis. (Boucher's Clinical Dental Terminology, 4th ed, p239)
Measurement of oxygen and carbon dioxide in the blood.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
A colorless, odorless gas that can be formed by the body and is necessary for the respiration cycle of plants and animals.
Arteries which arise from the abdominal aorta and distribute to most of the intestines.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration.
Agents that prevent clotting.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Vegetative state refers to the neurocognitive status of individuals with severe brain damage, in whom physiologic functions (sleep-wake cycles, autonomic control, and breathing) persist, but awareness (including all cognitive function and emotion) is abolished.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
Colloids with liquid continuous phase and solid dispersed phase; the term is used loosely also for solid-in-gas (AEROSOLS) and other colloidal systems; water-insoluble drugs may be given as suspensions.
The pharmacological result, either desirable or undesirable, of drugs interacting with components of the diet. (From Stedman, 25th ed)
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
The giving of drugs, chemicals, or other substances by mouth.
Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)
Hard or soft soluble containers used for the oral administration of medicine.
A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.
Available manpower, facilities, revenue, equipment, and supplies to produce requisite health care and services.
A versatile contrast medium used for DIAGNOSTIC X-RAY RADIOLOGY.
Substances used to allow enhanced visualization of tissues.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Small encapsulated gas bubbles (diameters of micrometers) that can be used as CONTRAST MEDIA, and in other diagnostic and therapeutic applications. Upon exposure to sufficiently intense ultrasound, microbubbles will cavitate, rupture, disappear, release gas content. Such characteristics of the microbubbles can be used to enhance diagnostic tests, dissolve blood clots, and deliver drugs or genes for therapy.
Gadolinium. An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.
A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.

Delayed gastric emptying after Billroth I pylorus-preserving pancreatoduodenectomy: effect of postoperative time and cisapride. (1/1045)

OBJECTIVE: To study the recovery course of gastric emptying after Billroth I pylorus-preserving pancreatoduodenectomy (PPPD) and therapeutic effects of cisapride. METHODS: To examine gastric emptying, acetaminophen was given, admixed in a pasty liquid meal, to 16 patients undergoing PPPD before surgery and at 1, 3, 6, 9, and 12 months after surgery. Cisapride was given orally to 10 patients before they received the acetaminophen regimen. Electrogastrography was performed at 2 weeks to 1 month after surgery in eight patients and at 6 to 12 months after surgery in seven patients. RESULTS: Gastric emptying was delayed but returned to the preoperative level by 6 months after surgery. Pretreatment with cisapride accelerated gastric emptying during months 1 to 6 but not during months 6 to 12 after surgery. Electrogastrography frequently showed tachygastria 2 weeks to 1 month after surgery, but seldom 6 to 12 months after surgery. CONCLUSIONS: After Billroth I PPPD, gastric emptying is delayed but recovers by 6 months after surgery. Tachygastria may play a part in the pathogenesis of delayed gastric emptying, but it can be treated with cisapride.  (+info)

Erythromycin enhances early postoperative contractility of the denervated whole stomach as an esophageal substitute. (2/1045)

OBJECTIVE: To determine whether early postoperative administration of erythromycin accelerates the spontaneous motor recovery process after elevation of the denervated whole stomach up to the neck. SUMMARY BACKGROUND DATA: Spontaneous motor recovery after gastric denervation is a slow process that progressively takes place over years. METHODS: Erythromycin was administered as follows: continuous intravenous (i.v.) perfusion until postoperative day 10 in ten whole stomach (WS) patients at a dose of either 1 g (n = 5) or 2 g (n = 5) per day; oral intake at a dose of 1 g/day during 1.5 to 8 months after surgery in 11 WS patients, followed in 7 of them by discontinuation of the drug during 2 to 4 weeks. Gastric motility was assessed with intraluminal perfused catheters in these 21 patients, in 23 WS patients not receiving erythromycin, and in 11 healthy volunteers. A motility index was established by dividing the sum of the areas under the curves of >9 mmHg contractions by the time of recording. RESULTS: The motility index after IV or oral administration of erythromycin at and after surgery was significantly higher than that without erythromycin (i.v., 1 g: p = 0.0090; i.v., 2 g: p = 0.0090; oral, 1 g: p = 0.0017). It was similar to that in healthy volunteers (i.v., 1 g: p = 0.2818; oral, 1 g: p = 0.7179) and to that in WS patients with >3 years of follow-up who never received erythromycin (i.v., 1 g: p = 0.2206; oral, 1 g: p = 0.8326). The motility index after discontinuation of the drug was similar or superior to that recorded under medication in four patients who did not experience any modification of their alimentary comfort, whereas it dropped dramatically parallel to deterioration of the alimentary comfort in three patients. CONCLUSIONS: Early postoperative contractility of the denervated whole stomach pulled up to the neck under either i.v. or oral erythromycin is similar to that recovered spontaneously beyond 3 years of follow-up. In some patients, this booster effect persists after discontinuation of the drug.  (+info)

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. (3/1045)

PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS: Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.  (+info)

Is maintenance therapy always necessary for patients with ulcerative colitis in remission? (4/1045)

BACKGROUND: The efficacy of sulphasalazine and mesalazine in preventing relapse in patients with ulcerative colitis is well known. It is less clear how long such maintenance should be continued, and if the duration of disease remission is a factor that affects the risk of recurrence. AIM: To determine whether the duration of disease remission affects the relapse rate, by comparing the efficacy of a delayed-release mesalazine (Asacol, Bracco S.p.A., Milan, Italy) against placebo in patients with ulcerative colitis with short- and long-duration of disease remission. METHODS: 112 patients (66 male, 46 female, mean age 35 years), with intermittent chronic ulcerative colitis in clinical, endoscopic and histological remission with sulphasalazine or mesalazine for at least 1 year, were included in the study. Assuming that a lower duration of remission might be associated with a higher relapse rate, the patients were stratified according to the length of their disease remission, prior to randomization into Group A (Asacol 26, placebo 35) in remission from 1 to 2 years, or Group B (Asacol 28, placebo 23) in remission for over 2 years, median 4 years. Patients were treated daily with oral Asacol 1.2 g vs. placebo, for a follow-up period of 1 year. RESULTS: We employed an intention-to-treat analysis. In Group A, whilst no difference was found between the two treatments after 6 months, mesalazine was significantly more effective than placebo in preventing relapse at 12 months [Asacol 6/26 (23%), placebo 17/35 (49%), P = 0.035, 95% Cl: 48-2.3%]. In contrast, in Group B no statistically significant difference was observed between the two treatments, either at 6 or 12 months [Asacol 5/28 (18%), placebo 6/23 (26%), P = 0.35, 95% Cl: 31-14%] of follow-up. Patients in group B were older, and had the disease and remission duration for longer, than those in Group A. CONCLUSIONS: Mesalazine prophylaxis is necessary for the prevention of relapse by patients with ulcerative colitis in remission for less than 2 years, but this study casts doubt over whether continuous maintenance treatment is necessary in patients with prolonged clinical, endoscopic and histological remission, who are at very low risk of relapse.  (+info)

Bile salts: natural detergents for the prevention of sexually transmitted diseases. (5/1045)

The development of new, safe, topical microbicides for intravaginal use for the prevention of sexually transmitted diseases is imperative. Previous studies have suggested that bile salts may inhibit human immunodeficiency virus infection; however, their activities against other sexually transmitted pathogens have not been reported. To further explore the potential role of bile salts in preventing sexually transmitted diseases, we examined the in vitro activities and cytotoxicities of select bile salts against Chlamydia trachomatis, herpes simplex virus (types 1 and 2), Neisseria gonorrhoeae, and human immunodeficiency virus in comparison to those of nonoxynol-9 and benzalkonium chloride using both primary cells and cell lines derived from the human female genital tract. We found that taurolithocholic acid 3-sulfate and a combination of glycocholic acid and taurolithocholic acid 3-sulfate showed excellent activity against all of the pathogens assayed. Moreover, taurolithocholic acid 3-sulfate alone or in combination was less cytotoxic than nonoxynol-9 and benzalkonium chloride. Thus, taurolithocholic acid 3-sulfate alone or in combination warrants further evaluation as a candidate topical microbicidal agent.  (+info)

Clinical considerations in GERD (gastroesophageal reflux disease) therapy: focus on cisapride. (6/1045)

Heartburn, the major symptom of gastrointestinal reflux disease (GERD), is a common condition that is usually self-treated with over-the-counter products. For patients with severe or recurrent symptoms of GERD, pharmacologic therapy includes acid suppression with H2-receptor antagonists and proton pump inhibitors, and, alternatively, the use of prokinetic agents. While all of these are efficacious, given its high efficacy in nonerosive and mild-to-moderate erosive esophagitis, the prokinetic agent cisapride deserves significant consideration in this patient population.  (+info)

Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial. (7/1045)

AIM: To determine the effect of erythromycin on the establishment of enteral feeding in ventilated infants < 31 weeks gestation. METHODS: Erythromycin was randomly allocated as an antimicrobial treatment for the first 7 days of life in 76 infants: 35 received erythromycin and 41 acted as controls. Feed toleration, time taken to establish full enteral feeding, vomiting, prescription of glycerine suppositories and occurrence of necrotising enterocolitis were recorded. RESULTS: There were no significant differences between the groups for any of the outcomes. The infants treated with erythromycin reached full feeding at a median (quartile) age of 8 (5-12) days compared with 9 (6-14) days for controls. CONCLUSIONS: Intravenous erythromycin in antimicrobial doses is unlikely to benefit the introduction of feeding in preterm infants.  (+info)

Characterization of a Na+-dependent betaine transporter with Cl- channel properties in squid motor neurons. (8/1045)

Most marine invertebrates, including squids, use transporters to accumulate organic osmolytes such as betaine, to prevent water loss when exposed to elevated salinity. Although a limited number of flux studies have shown the Na+ dependence of betaine transport, nothing is known about the electrogenic properties of osmolyte transporters. We used whole cell and perforated-patch voltage-clamp techniques to characterize the electrical properties of the betaine transporter in giant fiber lobe motor neurons of the squid Lolliguncula brevis. Betaine activated a large, Cl--selective current that was reversibly blocked by 100 microM niflumic acid (97 +/- 2% block after 40 s, SD; n = 7) and partially inhibited by 500 microM SITS (29 +/- 11%; n = 5). The Cl- current was Na+ dependent and was virtually eliminated by isotonic replacement of Na+ with Li+, NMDG+, or Tris+. Concentration-response data revealed an EC50 in a physiologically relevant range for these animals of 5.1 +/- 0.9 mM (n = 11). In vertebrates, the betaine transporter is structurally related to the GABA transporter, and although GABA did not directly activate the betaine-induced current, it reversibly reduced betaine responses by 34 +/- 14% (n = 8). Short-term changes in osmolality alone did not activate the Cl- current, but when combined with betaine, Cl- currents increased in hypertonic solutions and decreased in hypotonic solutions. Activation of the betaine transporter and Cl- current in hypertonic conditions may affect both volume regulation and excitability in L. brevis motor neurons. This study is the first report of a novel betaine transporter in neurons that can act as a Cl- channel.  (+info)

The rationale for anti-tumour necrosis factor-alpha (anti-TNFalpha) therapy in rheumatoid arthritis (RA) is based on experiments on cultures of human rheumatoidjoint tissue, supported by experiments in animal models, all of which demonstrated that anti-TNFalpha antibody had profound effects on the
Can you get remicade (infliximab) infusion when you have a cold? Answered by Dr. Ronald Krauser: Maybe: If it is very minor, yes. If it is more severe and if you have ...
You are at: Home » Products » Pharmaceuticals and Biochemicals » Gastrointestinal agentsIn total 699093 number ofProductsinfo,Released today. 0 number of ...
You are at: Home » Products » Pharmaceuticals and Biochemicals » Gastrointestinal agentsIn total 717051 number ofProductsinfo,Released today. 0 number of ...
TY - JOUR. T1 - Effects of GC7101, a novel prokinetic agent on gastric motor function. T2 - Ex vivo study. AU - Jung, Da Hyun. AU - Choi, Eun Ju. AU - Jeon, Han Ho. AU - Lee, Young Ho. AU - Park, Hyojin. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Background/Aims: GC7101, an extract of Lonicera Flos, is a novel developing drug for reflux esophagitis and functional dyspepsia. However, the drugs exact pharmacological mechanism of action remains unclear. This study assessed the effects of GC7101 on gastrointestinal (GI) motor function. Methods: We used male guinea pigs to evaluate the effects of GC7101 on GI motility. The contraction of antral circular muscle in the presence of different doses of GC7101 was measured in a tissue bath. The prokinetic effects of GC7101 were tested using the charcoal transit assay from the pylorus to the most distal point of migration of charcoal mixture. To clarify the mechanism of action of GC7101, atropine, dopamine and the selective 5-hydroxytryptamine 4 receptor ...
Looking for online definition of Gastrointestinal agents in the Medical Dictionary? Gastrointestinal agents explanation free. What is Gastrointestinal agents? Meaning of Gastrointestinal agents medical term. What does Gastrointestinal agents mean?
The Gastrointestinal agents Directory Page3 for Global and China Gastrointestinal agents Suppliers and Gastrointestinal agents Manufacturers is managed by ChemIndex
The most recent publication of the Clinical Gastroenterology & Hepatology evaluates rates of response to placebo in trials of patients with fistulizing Crohns disease ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
In Australia so see it each time inflix approval needed. Relys too much on diarrhoea which for me is controlled by pain killers im on. Also only looks at a 2 week window - I could be shocking beforehand but then improve just when the cdai is done. Not sure how they can improve on it and it at least provides some info. Better then nothing. I estimated my cdai as 438, guessing what crp is,at he moment - not sure how this reflects severity but am presently in hospital with abscesses and inflammation of small bowel - and picked up c diff too. So cdai is being skewed by painkillers and anti ds. Just needs to be used as one tool in the gis arsenal of not much else. haha ...
In this article, we break down what exactly prokinetics are, and why they can be a necessary part of treatment for many functional gut disorders.
In this article, we break down what exactly prokinetics are, and why they can be a necessary part of treatment for many functional gut disorders.
BACKGROUND: Infliximab withdrawal in patients with Crohns disease on concomitant antimetabolite therapy is considered to be superior if obtained after a maintenance therapy period compared to induction alone.. METHODS: We retrospectively analyzed the outcome of Crohns disease patients treated with infliximab and an antimetabolite after infliximab was withdrawn using induction alone or induction plus at least 1-year of maintenance therapy. The time to relapse was analyzed using univariate and multivariate analyses. The model was adjusted according to the period of infliximab withdrawal.. RESULTS: A total of 92 patients were included, 54 in the induction alone group. The patient characteristics were identical in the two groups except for the period of infliximab withdrawal. After a median follow-up period of 47.1 (interquartile range=4.4-110.2) months, 66 patients (72%) experienced a relapse. After a year-adjustment, no significant difference was observed between the two groups. Based on ...
This is a multi-centre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of two oral doses of GSK1605786A (500 mg once daily, 500 mg twice daily) as compared to placebo in the induction of clinical response over a 12-week treatment period in subjects with moderately-to-severely active Crohns disease. Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of remission.. The study is planned to randomise approximately 600 subjects (200 subjects/group) with active Crohns disease, diagnosed for at least 4 months with a documented history of disease in the small and/or large intestine, and characterised by a Crohns Disease Activity Index (CDAI) score between 220 to and 450, inclusive. Subjects must have reported an inadequate response or intolerance to Crohns disease treatment with corticosteroids or immunosuppressants. Inclusion of subjects who received prior treatment with a biologic anti-tumour necrosis ...
TY - JOUR. T1 - Mechanism of the acetylcholine-release effect of cisapride on guinea-pig gastrointestinal tract. AU - Chen, H. T.. AU - Pan, S.. PY - 1988/1/1. Y1 - 1988/1/1. UR - http://www.scopus.com/inward/record.url?scp=0023689373&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0023689373&partnerID=8YFLogxK. M3 - Article. C2 - 3179814. AN - SCOPUS:0023689373. VL - 41. SP - 263. EP - 270. JO - Journal of the Chinese Medical Association. JF - Journal of the Chinese Medical Association. SN - 1726-4901. IS - 4. ER - ...
We acknowledge that human health is our essential and top priority responsibility along the healing journey we started in 1912. This responsibility encourages us to do our job meticulously, fully, accurately and honestly and thus we always set the highest standards in parallel to this goal because we believe that the way we do business in the path to success is as important as our achievements, at the very least ...
Cisapride + methylpolysiloxane is used in the treatment of .get complete information about cisapride + methylpolysiloxane including usage, side effects, drug interaction, expert advice along with medicines associated with cisapride + methylpolysiloxane at 1mg.com
Cisapride is one of the frequently used prokinetic agent used in a variety of GIT disorders by virtue of its effects of its 5 HT receptor agonism.
Infliximab therapy is associated with an attenuated serological responses to SARS-CoV-2 infection that can be further blunted by immunomodulators.
Medical information for Mosapride on Pediatric Oncall including Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction.
Detailed drug Information for tegaserod. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
In patients with ASUC, an accelerated infliximab induction strategy reduces the need for early colectomy. An intensified infliximab dosing strategy in response to clinical or laboratory signs of breakthrough inflammation merits consideration in prospective studies.
This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will
Qing Ke Yi is a medicine available in a number of countries worldwide. A list of US medications equivalent to Qing Ke Yi is available on the Drugs.com website.
Remicade (Infliximab) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
Посетительница выставки по имени Би Цин (Bi Qing) уверена, что на фоне процветания и роста китайской экономики она будет потреблять всё больше зарубежных продуктов. Таким образом, выставка принесёт ей дополнительные варианты и сюрпризы.. По словам представителей оргкомитета, кроме традиционных товаров вроде чая, шёлка и фарфора на выставке будут также представлены другие знаменитые продукты - шриланкийские сапфиры и чёрный чай, иранские шёлковые изделия, шафран и орехи, русская водка и мёд, юго-африканские алмазы и алоэ, итальянское вино и ...
Top on the web betting house Review articles! I manifest of which What im through 18 years old and additionally Document have read and consented to the actual:
The objectives of the study were to determine whether retrospective data can be used to answer questions about the efficacy of prokinetic agents when used to treat horses with post-operative ileus (POI). We describe prevalence and mortality of POI with reference to treatment with four prokinetic agents. By combining data from two Hospitals a study population of 55 horses with POI following pedunculated lipoma obstruction (PLO) was established. Univariable and multivariable associations were determined between short term survival and potential explanatory variables. With death as outcome in multivariable models, breed and hospital were significantly associated with outcome but the use of prokinetic agents was not (P=0.15). However, sample size estimates indicate the low power of this study to detect differences in outcome. It was not possible definitively to evaluate the efficacy of prokinetics as treatment for POI following PLO using retrospective data. The data were suggestive of limited ...
Our results indicate that VLBW infants with feed intolerance due to non-anatomically obstructive gastrointestinal dysmotility achieved full enteral feeding significantly earlier after treatment with oral erythromycin. The median times taken to establish half, three quarters, and full enteral nutrition were 3.5, 8.5, and 13.5 days after the start of oral erythromycin. The median times taken to achieve half and full oral feeding in the placebo group were almost twice as long (table2). These findings agree with those of previous case series in preterm infants.13-15 Although a recent randomised controlled study did not show any benefit of intravenous erythromycin in improving the tolerance of enteral feeding in preterm infants,25these findings were not entirely unexpected because the study was not primarily designed to investigate the effectiveness of erythromycin on enteral feeding, but rather focused on the relation between chronic lung disease and intravenous erythromycin treatment for ...
TY - JOUR. T1 - Crohns disease. T2 - Rational management. AU - Picco, Michael F.. PY - 2002. Y1 - 2002. N2 - Crohns disease can involve any part of the digestive tract; it can manifest as inflammatory (diarrhea, abdominal pain, and fever), penetrating (abscess or fistula), or stricturing (recurrent bowel obstruction) disease. Treatment is based on the location and activity of the disease. Mesalamine is recommended to induce and maintain remission in patients with mild to moderate nonpenetrating, nonstricturing disease. Antibiotics may be used as an alternative or adjunct to mesalamine; ciprofloxacin and metronidazole are helpful in fistulizing Crohns disease. For patients with moderate to severe disease, corticosteroids are recommended to induce remission; infliximab is an alternative for those with severe or refractory disease. Remission is then maintained with immunosuppressive therapy, not with corticosteroids. Fistulas are difficult to treat but may respond to antibiotics or azathioprine; ...
Practical and objective instruments to assess pediatric Crohns disease (CD) activity are required for observational research and quality improvement. The objectives were: 1) to determine the feasibility of completing the Pediatric Crohns Disease Activity Index (PCDAI) and the Abbreviated PCDAI (APCDAI); and 2) to create a Short PCDAI by retaining and reweighting the most practical and informative components.
The researchers found that 98% of policies are inconsistent with the AGA ulcerative colitis pathway and require step-wise drug failure before approval of an anti-TNF. Only 11% of the policies allowed starting vedolizumab without initial failures of an anti-TNF agent, and 21% required the failure of 2 or more anti-TNF agents. The team noted that 90% of the policies are inconsistent with AGA Crohns disease pathway, and require step-wise drug failure before approval of an anti-TNF. The research team found that 74% allowed for initiating infliximab specifically for fistulizing Crohns disease. The team observed that 28% required failing of at least 2 or more drugs before starting anti-TNF. Only 8% of policies allowed starting vedolizumab without initial failures of an anti-TNF agent, and 28% required the failure of two anti-TNF agents.. Dr Feuersteins team concludes, The majority of the policies reviewed fail to adhere to the current AGA pathway recommendations for ulcerative colitis and Crohns ...
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, vanDeventer SJ: Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004 Feb 26;350(9):876-85. PMID 14985485 ...
TY - JOUR. T1 - Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab. T2 - A retrospective analysis of the ACCENT i trial. AU - Cornillie, Freddy. AU - Hanauer, Stephen B.. AU - Diamond, Robert H.. AU - Wang, Jianping. AU - Tang, Kezhen L.. AU - Xu, Zhenhua. AU - Rutgeerts, Paul. AU - Vermeire, Séverine. PY - 2014/11/1. Y1 - 2014/11/1. N2 - Background Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohns disease who stop responding to infliximab treatment.Objective To carry out a post hoc analysis of A Crohns Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen I (ACCENT I) to evaluate the association between serum infliximab trough levels and C-reactive protein (CRP) after 14 weeks of induction treatment with durable sustained long-term response (Crohns Disease Activity Index decrease ≥70 points and ...
Functional Dyspepsia Market. Functional Dyspepsia Market Size is anticipated to increase during the study period owing to the increase in geriatric population and changing dietary habits in the 7MM which increase the cases of FD.. The Functional Dyspepsia market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Functional Dyspepsia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. The report gives a thorough detail of the Functional Dyspepsia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. Functional Dyspepsia Epidemiology. The Functional Dyspepsia epidemiology ...
Prokinetic AgentsProkinetics are promotility agents proposed for use in patients with severe constipation-predominant symptoms. Prucalopride (Motegrity)Prucalopride, a selective 5-hydroxytryptamine (s... more
TY - ABST. T1 - Treatment of Secondary Infliximab Failure in Crohns Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab. T2 - The Danish Study of Optimizing Infliximab Therapy in Crohns Disease (Do It Crohn) Randomized Clinical Trial. AU - Steenholdt, Casper. AU - Brynskov, Jorn. AU - Thomsen, Ole.. AU - Munck, Lars K.. AU - Fallingborg, Jan. AU - Christensen, Lisbet A.. AU - Pedersen, Gitte. AU - Kjeldsen, Jens. AU - Jacobsen, Bent A.. AU - Oxholm, Anne Sophie. AU - Kjellberg, Jakob. AU - Bendtzen, Klaus. AU - Ainsworth, Mark A.. PY - 2013. Y1 - 2013. U2 - 10.1016/S0016-5085(13)60074-8. DO - 10.1016/S0016-5085(13)60074-8. M3 - Conference abstract in journal. VL - 144. SP - 22 JO - Gastroenterology. JF - Gastroenterology. SN - 0016-5085. IS - 5, Supplement 1. M1 - 94. ER - ...
There is a great need to define molecular mechanisms that underlie (non-)response to anti-TNFα therapy in ulcerative colitis. In this study we investigated endoscopic mucosal biopsy derived mRNA expression to identify a gene expression fingerprint distinguishing primary non-responders from responders and to identify gene panels predictive of response to infliximab, a chimeric IgG1 monoclonal antibody to TNFα.. Two independent cohorts of patients with refractory ulcerative colitis who received a first treatment with infliximab were studied. We classified patients as responders if they achieved complete healing both endoscopically and histologically. All other patients were considered non-responders although some of them showed clinical improvement or showed mucosal healing at a later time point. We used mucosal healing as an endpoint as it is less open to bias than a symptom score, and there is little chance that complete mucosal healing would occur only by spontaneous disease ...
Tolerability of Shortened Infliximab Infusion in Scheduled Maintenance Therapy for IBD: a Prospective Multi-center European Cohort Study
MODEL RELEASED. Infusion pump (Baxter Colleague) used to administer an intravenous (IV) infusion of infliximab into a male patient with Crohns disease. Infliximab is a monoclonal antibody used to treat inflammatory Crohns disease. Sequence of images. - Stock Image C016/8148
Looking for online definition of infliximab in the Medical Dictionary? infliximab explanation free. What is infliximab? Meaning of infliximab medical term. What does infliximab mean?
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Reinisch and colleagues (Gut 2006;55:1138-44) recently reported that the infusion of fontolizumab, an anti-interferon γ antibody, into patients with Crohns disease was generally well tolerated with encouraging clinical responses. Unfortunately, not all first trials with therapeutic antibodies go as well as planned. As we recently witnessed with the intravenous administration of TGN1412, designed to activate regulatory T cells for the treatment of leukaemia and autoimmune diseases such as rheumatoid arthritis, six volunteers were hospitalised, four of whom suffered major organ failure. The patients conditions was described as cytokine release syndrome which occurs when activated T cells produce a systemic inflammatory response.. Could the violent reaction to the monoclonal antibody be avoided with oral administration? Ochi et als recent report may offer an answer. They observed that oral was as effective as intravenous administration of anti-CD3 in reversing established experimental ...
AIM: To study the effects of infliximab on pregnancy and foetal outcome. METHODS: We conducted a retrospective chart review of women with Crohns disease treated intentionally with infliximab during pregnancy. The primary outcome measure was the occu
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. As well as providing superior treatments for immune-mediated inflammatory diseases (IMIDs), such therapies also offer unrivalled opportunities to study the underlying immunopathological basis of these conditions.. In this review, we explore recent approaches to the treatment of IMIDs and the insights to pathobiology that they provide. We review novel biologic agents targeting the T-helper 17 axis, including therapies directed towards interleukin (IL)-17 (secukinumab, ixekizumab, bimekizumab), IL-17R (brodalumab), IL-12/23p40 (ustekinumab, briakinumab) and IL-23p19 (guselkumab, tildrakizumab, brazikumab, risankizumab, mirikizumab). We also present an overview of biologics active against type I and II interferons, including sifalumumab, rontalizumab, anifrolumab and fontolizumab. Emerging ...
Hi, my daughter had her Infliximab infusion last Wed 8th Jan, she has been having them since last May and after the initial loading doses is on an 8 week maintenance. Ella previously had 3 loading doses starting Oct 2012 but they were discontinued due to possible joint pains ( the doctors never came to a conclusion) anyway it was decided after Ella wasnt maintaining on the Aza that she would have to restart. Mostly the infusions have been ok, she has had joint pain (ankle and Knee) but we decided it was the lesser of two evils ...
Thank you for your interest in spreading the word about The Journal of Rheumatology.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
A recent case series (A Assa et al. JPGN 2020; 71: 516-520. Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series) describes four infants (2 mo-12 mo) with infantile-onset IBD who received high doses of infliximab. Treatments regimens utilized infliximab dosing of 10-22 mg/kg/dose with initial three doses over 2-4 weeks.…
A pathway that may contribute to the symptoms related to Crohns disease and ulcerative colitis has been identified by researchers
The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohns disease activity Index
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
This is a randomized, double-blind, placebo-controlled, parallel-group multicenter study of the safety and efficacy of SC regimens of ustekinumab in maintaining disease control through Week 44 in subjects with moderately to severely active Crohns disease induced into clinical response with ustekinumab in the induction studies, CNTO1275CRD3001 or CNTO1275CRD3002. The maintenance portion of the study continues to Week 44 and the subsequent study extension will continue up to Week 272. The number of subjects enrolling in this study will be dependent on the number of subjects from the induction studies eligible to enroll into the maintenance study.. In summary, there is a significant medical need for new safe and effective therapies for moderate to severe, active Crohns disease, particularly in patients who have failed to respond to TNF antagonists. Inhibiting IL-12 and IL-23 and their associated inflammatory pathways via. blockade of the shared IL-12 p40 subunit by ustekinumab constitutes a novel ...
Find REMICADE® (infliximab) infusion centers for the treatment of active Ankylosing spondylitis. See full Prescribing and Safety Information.
Management of functional dyspepsia in 2020: a clinical point of view - Minerva Gastroenterologica e Dietologica 2020 December;66(4):331-42 - Minerva Medica - Journals
Rifaximin is an antibiotic used to treat diarrhea induced by the common bacteria known as E. coli. It stops the growth of bacteria in the body. Know more about Rifaximin!
Cisapride: | | Cisapride | | | ||| | | | ... World Heritage Encyclopedia, the aggregation of the largest online encyclopedias available, and the most definitive collection ever assembled.
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohns Disease Patients With Loss of Response
What is indigestion dyspepsia? It is an impaired digestion with feeling of fullness discomfort after meals without any organic disease.
The Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohns disease, a chronic
Infliximab è un anticorpo monoclonale che è amministrato per via endovenosa per curare i pazienti con le malattie infiammatorie croniche compreso il morbo di Crohn, la colite ulcerosa, lartrite
WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of REMICADE (INFLIXIMAB) based in New Delhi, India
Medical information for Erythromycin on Pediatric Oncall including Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose.
Rifaximine - Buy Rifaximine Online At Low Cost From Erectile Wellness ✔ Use rifaximin with lactulose at the maximum tolerated dose✔ rifaximin side effects.
Hello Grateful for any advice. Funding has been put forward to my PCT for Remicade infusions but my hospital warned that the borough I live is notorio...
Jun Zou, Wen-Qing Li, Qing Li, Xiang-Qi Li, Jun-Tao Zhang, Gan-Qiang Liu, Jian Chen, Xiao-Xu Qiu, Fu-Ju Tian, Zhi-Zhang Wang, Ni Zhu, Yong-Wen Qin, Bairong Shen, Ting Xi Liu, Qing Jing ...
Research indicates rifaximin might help this subset of people with IBS. Individuals suffering from IBS also benefit by keeping a diary of food & drink consumed.
Virology is proud to present this Essential Collection of the 30 review articles that we published in 2013 (in addition to our Special Issue on...
... a motilin agonist and gastrointestinal prokinetic agent". The American Journal of Gastroenterology. 88 (4): 485-90. PMID ... If mitemcinal can be shown to be an effective prokinetic agent, it would represent a significant advance in the ... August 2016). "The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a ... Antimicrobial Agents and Chemotherapy. 28 (5): 630-3. doi:10.1128/aac.28.5.630. PMC 176346. PMID 4091529. Pal S (2006). "A ...
Contrast agent Lower gastrointestinal series Cittadini, Giorgio (2012). Double contrast barium enema: The Genoa approach. ... A liquid containing barium (that is, a radiocontrast agent) is put into the rectum. Barium is a silver-white metallic compound ... Stringer, David A.; Babyn, Paul S. (2000). Pediatric Gastrointestinal Imaging and Intervention. PMPH-USA. p. 38. ISBN ...
"Bile acids as endogenous etiologic agents in gastrointestinal cancer". World J. Gastroenterol. 15 (27): 3329-40. doi:10.3748/ ... Gastrointestinal and Liver Physiology. 318 (3): G554-G573. doi:10.1152/ajpgi.00223.2019. PMC 7099488. PMID 31984784. Kim, I; ... is a semi-synthetic bile acid with greater activity as FXR agonist which is undergoing investigation as a pharmaceutical agent ...
Bernstein H, Bernstein C, Payne CM, Dvorak K (July 2009). "Bile acids as endogenous etiologic agents in gastrointestinal cancer ... Genotoxins include chemical agents like N-nitroso-N-methylurea (NMU) or non-chemical agents such as ultraviolet light and ... Lead and its compounds Alkylating antineoplastic agents (e.g. mechlorethamine) Styrene Other alkylating agents (e.g. dimethyl ... Group 3: the agent (mixture or exposure circumstance) is not classifiable as to its carcinogenicity to humans. Group 4: the ...
Somerville KW, Hawkey CJ (January 1986). "Non-steroidal anti-inflammatory agents and the gastrointestinal tract". Postgraduate ... In three of the six species benoxaprofen was then effectively taken up from the gastrointestinal tract (after oral doses of 1- ... The free radical decarboxylated derivative of the drug is the toxic agent which, in the presence of oxygen, yields singlet ... Gastrointestinal side effects of benoxaprofen are bleeding, diarrhoea, abdominal pain, anorexia (symptom), mouth ulcers and ...
Although rarely, the agent can cause gastrointestinal disease which does not show specific vulnerable groups or risk factors. ... "Basidiobolus ranarum as an Etiologic Agent of Gastrointestinal Zygomycosis". Journal of Clinical Microbiology. 39 (6): 2360- ... As well, the agent may transmit through traumas or insect bites on skin. Most of the reported cases were from Nigeria and ... Ingestion of B. ranarum is thought to help disperse the agent through the deposition of feces at a distant place where human ...
Gastrointestinal alkalizing (acidifying) agents increase the absorption of amphetamine. Urinary alkalizing (acidifying) agents ... Such agents also have important therapeutic uses; cocaine, for example, is used as a local anesthetic (Chapter 2), and ... Duration of effect varies depending on agent and urine pH. Excretion is enhanced in more acidic urine. Half-life is 7 to 34 ... Gastrointestinal side effects may include abdominal pain, constipation, diarrhea, and nausea. Other potential physical side ...
Gismondo MR, Drago L, Lombardi A (1999). "Review of probiotics available to modify gastrointestinal flora". Int. J. Antimicrob ... Alvarez-Olmos MI, Oberhelman RA (2001). "Probiotic agents and infectious diseases: a modern perspective on a traditional ... International Journal of Antimicrobial Agents. 22 (4): 360-6. doi:10.1016/S0924-8579(03)00153-5. PMID 14522098.. ... such as reducing gastrointestinal discomfort, improving immune health,[8] relieving constipation, or avoiding the common cold, ...
gastrointestinal agent (en) Identifikatzaileak. InChlKey. JCQLYHFGKNRPGE-FCVZTGTOSA-N. CAS zenbakia. 4618-18-2. ...
"Bile acids as endogenous etiologic agents in gastrointestinal cancer". World J Gastroenterol. 15 (27): 3329-3340. doi:10.3748/ ... Genotoxins include chemical agents like N-nitroso-N-methylurea (NMU) or non-chemical agents such as ultraviolet light and ... Occupational carcinogens are agents that pose a risk of cancer in several specific work-locations:. Carcinogen. Associated ... Group 4: the agent (mixture) is probably not carcinogenic to humans.. Globally Harmonized SystemEdit. The Globally Harmonized ...
"Bile acids as endogenous etiologic agents in gastrointestinal cancer". World Journal of Gastroenterology. 15 (27): 3329-40. doi ... Genotoxins include chemical agents like N-nitroso-N-methylurea (NMU) or non-chemical agents such as ultraviolet light and ... Occupational carcinogens are agents that pose a risk of cancer in several specific work-locations: Carcinogen. Associated ... Group 2A: the agent (mixture) is probably (product more likely to be) carcinogenic to humans. The exposure circumstance entails ...
Potassium can bind to agents in the gastrointestinal tract.[34][35] Sodium polystyrene sulfonate with sorbitol (Kayexalate) has ... 2013). "Gastrointestinal adverse events with sodium polystyrene sulfonate (kayexalate) use: a systematic review.". Am J Med. ... Patiromer is a selective sorbent that is taken by mouth and works by binding free potassium ions in the gastrointestinal tract ... Potassium is eliminated from the body through the gastrointestinal tract, kidney and sweat glands. In the kidneys, elimination ...
Mediators and Drugs in Gastrointestinal Motility II: Endogenous and Exogenous Agents. Springer Science & Business Media. 6 ... Schuermans V, Van Lommel R, Dom J, Brugmans J (1974). "Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: ... It is an antifoaming agent used to reduce bloating, discomfort, or pain caused by excessive gas. Drugs.com International brands ... Loperamide is an antidiarrheal agent, which decreases intestinal movement. As such, when combined with other antimotility drugs ...
Less commonly gastrointestinal or urinary infection can be the inciting agent. All of these infections have in common the ... Several chemotherapeutic agents, for example Cisplatin, are associated with acute and chronic kidney injuries. Newer agents ... toxicity of chemotherapy agents, and long-term exposure to lead or its salts. Chronic conditions that can produce nephropathy ... Anti-Allergy Agents in Medicinal Chemistry. 5 (2): 139-146. doi:10.2174/187152306776872442. Grünfeld, JP; Rossier, BC (May 2009 ...
"Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract" (PDF). Journal of Gastroenterology ... It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug ...
Potassium can bind to a number of agents in the gastrointestinal tract. Sodium polystyrene sulfonate with sorbitol (Kayexalate ... 2013). "Gastrointestinal adverse events with sodium polystyrene sulfonate (kayexalate) use: a systematic review". Am J Med. 126 ... Patiromer is taken by mouth and works by binding free potassium ions in the gastrointestinal tract and releasing calcium ions ... Potassium is eliminated from the body through the gastrointestinal tract, kidney and sweat glands. In the kidneys, elimination ...
Weber FH, Richards RD, McCallum RW (April 1993). "Erythromycin: a motilin agonist and gastrointestinal prokinetic agent". The ... "Antimicrobial Agents and Chemotherapy. 12 (5): 630-5. doi:10.1128/AAC.12.5.630. PMC 429989. PMID 21610.. ... "Antimicrobial Agents and Chemotherapy. 28 (5): 630-3. doi:10.1128/aac.28.5.630. PMC 176346. PMID 4091529.. ... Gastrointestinal disturbances, such as diarrhea, nausea, abdominal pain, and vomiting, are very common because erythromycin is ...
COX-2 selective agents such as celecoxib have a more limited gastrointestinal toxicity. NSAID injections of ketorolac can be ... These agents, although efficacious, were associated with intolerable side effects. The current armamentarium of hormonal agents ... Both agents inhibit the growth of endometriosis but their use has declined, due in part to virilizing side effects such as ... Pentoxifylline, an immunomodulating agent, has been theorized to improve pain as well as improve pregnancy rates in individuals ...
"Systematic review of agents for the management of gastrointestinal mucositis in cancer patients". Support Care Cancer. 21 (1): ... New agents have been identified in animal studies that may have effects on intestinal radiation injury. The research approach ... People who have been treated with radiotherapy for pelvic and other abdominal cancers frequently develop gastrointestinal ... nutritional deficiencies and weight loss abdominal pain and bloating nausea, vomiting and fatigue Gastrointestinal symptoms are ...
Lubiprostone is a gastrointestinal agent used for the treatment of constipation-predominant IBS. The use of antispasmodic drugs ... Sperber AD, Dekel R (April 2010). "Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal ... It acts as a bulking agent, and for many people with IBS-D, allows for a more consistent stool. For people with IBS-C, it seems ... Ferguson LR, Laing B, Marlow G, Bishop K (January 2016). "The role of vitamin D in reducing gastrointestinal disease risk and ...
... helps remove infectious agents.[2] Also, mucus traps infectious agents.[2] The gut flora can prevent the colonization of ... Gastrointestinal tract. Peristalsis, gastric acid, bile acids, digestive enzyme,. flushing, thiocyanate,[2] defensins,[2] gut ... Acting as a physical and chemical barrier to infectious agents; via physical measures like skin or tree bark and chemical ... The epithelial surfaces form a physical barrier that is impermeable to most infectious agents, acting as the first line of ...
Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents ... Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. „Hepatology", 2013. *↑ a b c d e f g h i j k l m n o ... An approach to gastrointestinal haemorrhage. „Veterinary Ireland Journa". *↑ a b c d e f g Deborah Silverstein, Kate Hopper: ... a b c d e Anthony J. DiMarino, Stanley B. Benjamin: Gastrointestinal Disease: An Endoscopic Approach. SLACK Incorporated, 2002 ...
... a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections". Expert Opin Pharmacother. 7 ... A causative agent for eye keratitis infection". Spectrochimica Acta Part A: Molecular Spectroscopy. 153: 714-21. Bibcode: ... Anderson, V. R.; Curran, M. P. (2007). "Nitazoxanide: A review of its use in the treatment of gastrointestinal infections". ... Antiparasitics target the parasitic agents of the infections by destroying them or inhibiting their growth; they are usually ...
It is likely the agent responsible for toxic (gastrointestinal) symptoms that occur in T. floccosus. It was described in 1947 ...
"Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal ... As a result, further development has commenced to bring more selective of anxiolytic agents to the market. An example of this ... Bouwer C, Stein DJ (April 1997). "Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in ... Evidence is not clear for panic disorder and functional gastrointestinal disorders. Side effects of azapirones may include ...
Less commonly gastrointestinal or urinary infection can be the inciting agent. All of these infections have in common the ... Several chemotherapeutic agents, for example Cisplatin, are associated with acute and chronic kidney injuries.[20] Newer agents ... Toxicity of chemotherapy agentsEdit. Main article: Onconephrology. Nephropathy can be associated with some therapies used to ... Anti-Allergy Agents in Medicinal Chemistry. 5 (2): 139-146. doi:10.2174/187152306776872442.. ...
Roberts DJ, Banh HL, Hall RI (August 2006). "Use of novel prokinetic agents to facilitate return of gastrointestinal motility ... It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as ... Galligan JJ, Vanner S (October 2005). "Basic and clinical pharmacology of new motility promoting agents". Neurogastroenterology ... dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable ...
Orally administered açaí has been tested as a contrast agent for magnetic resonance imaging (MRI) of the gastrointestinal ... April 2004). "Euterpe olerácea (Açaí) as an alternative oral contrast agent in MRI of the gastrointestinal system: preliminary ... Its anthocyanins have also been characterized for stability as a natural food coloring agent. A grove of açaí palms in Brazil ...
ISBN 978-0-312-42785-6. "Obesity Medication: Gastrointestinal Agents, Other, CNS Stimulants, Anorexiants, Glucagon-like Peptide ... Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications ... Catecholamine releasing agents such as amphetamine, phentermine, and related substituted amphetamines (e.g., bupropion) which ...
The rejection was based on concerns over the efficacy of the agent, as well as gastrointestinal side effects. Before issuing ... the clinical benefits of these agents have never been shown to outweigh the risks of their numerous adverse effects. Four ...
"Bile acids as endogenous etiologic agents in gastrointestinal cancer". World J. Gastroenterol. 15 (27): 3329-40. doi:10.3748/ ... Gastrointestinal and Liver Physiology. 318 (3): G554-G573. doi:10.1152/ajpgi.00223.2019. PMC 7099488. PMID 31984784.. ... is a semi-synthetic bile acid with greater activity as FXR agonist which is undergoing investigation as a pharmaceutical agent ...
Bile acid sequestrants may cause gastrointestinal problems and may also reduce the absorption of other drugs and vitamins from ... Hypolipidemic agents, cholesterol-lowering drugs or antihyperlipidemic agents, are a diverse group of pharmaceuticals that are ... Investigational classes of hypolipidemic agents: *CETP inhibitors (cholesteryl ester transfer protein), 1 candidate is in ... the choice of an agent depends on the patient's cholesterol profile, cardiovascular risk, and the liver and kidney functions of ...
Those species that seek pest insects are considered beneficial 'biological control agents' and their presence encouraged in ... There are environmental signals, signals from the gastrointestinal system, and metabolic signals that trigger hunger. The ...
97 patients were randomly assigned to one of the three groups: indinavir monotherapy, AZT and lamivudine, or all three agents. ... Gastrointestinal disturbances (abdominal pain, diarrhea, nausea, vomiting)[4]. *General malaise and fatigue[4] ...
... virus is classified as a biosafety level 4 agent, as well as a Category A bioterrorism agent by the Centers for Disease ... it is usually in the gastrointestinal tract.[35] The incidence of bleeding into the gastrointestinal tract was reported to be ~ ... Zubray G (2013). Agents of Bioterrorism: Pathogens and Their Weaponization. New York, NY, USA: Columbia University Press. pp. ... Sharma N, Cappell MS (September 2015). "Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection". Digestive ...
Hormonal agents[edit]. In women, the use of combined birth control pills can improve acne.[100] These medications contain an ... appears to have similar efficacy to 100 milligrams daily and has fewer gastrointestinal side effects.[15] However, low-dose ... "Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.. ... Hassoun LA, Chahal DS, Sivamani RK, Larsen LN (June 2016). "The use of hormonal agents in the treatment of acne". Seminars in ...
Main article: Radiocontrast agent. Contrast radiography uses a radiocontrast agent, a type of contrast medium, to make the ... Upper gastrointestinal series/Small-bowel follow-through/Lower gastrointestinal series. *Cholangiography/Cholecystography ... Contrast agents are required in conventional angiography, and can be used in both projectional radiography and computed ... Quader MA, Sawmiller CJ, Sumpio BE (2000). "Radio Contrast Agents: History and Evolution". Textbook of Angiology. pp. 775-783. ...
A local doctor concluded that some unspecified infectious agent had arrived in a package from New Orleans.[74][75] 650 ... and the gastrointestinal tract cause vomit containing blood, hence the Spanish name for yellow fever, vómito negro ("black ... The mosquito hypothetically considered as an agent in the transmission of yellow fever) Anales de la Real Academia de Ciencias ... "The mosquito hypothetically considered as an agent in the transmission of yellow fever poison," Archived 2017-02-23 at the ...
Chemical agents and related occupations, Volume 10, A review of Human Carcinogens, IARC Monographs, Lyon France 2009 [13] ... because the gastrointestinal tract protects itself against carcinomas by shedding its outer layer continuously.[citation needed ... A review of human carcinogens-part F: chemical agents and related occupations ... "Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract". Free Radic ...
... β-glucans are used as texturing agents in various nutraceutical and cosmetic products, and as soluble fiber supplements. ... "Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring ... "High-Amylose Resistant Starch Increases Hormones and Improves Structure and Function of the Gastrointestinal Tract: A ...
The initial site of infection may be the tonsils,[4] or possibly the gastrointestinal tract.[5] The virus then remains latent ... The JCV virus may also be a causative agent of aseptic meningitis (JCVM), as JCV was the only pathogen identified in the CSF of ... "JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract". Gastroenterology. 119 (5): ... recent literature has identified viral variants as etiological agents of other novel syndromes. For example, JCV has been found ...
... long-acting agents are recommended.[2] Long-acting agents partly work by reducing hyperinflation.[74] If long-acting ... Roflumilast and cilomilast may be associated with side effects such as gastrointestinal issues and weight loss. Sleep ... External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. Berylliosis. ... Several new long-acting agents are under development.[2] Treatment with stem cells is under study.[201] While there is ...
April 2011). "[Abdominal and gastrointestinal symptoms of Dengue fever. Analysis of a cohort of 8559 patients]". Gastroenterol ... "Opisthorchis felineus and Metorchis bilis are the main agents of liver fluke infection of humans in Russia". Parasitol. Int ... Organ EL, Rubin DH (1998). "Pathogenesis of reovirus gastrointestinal and hepatobiliary disease". Curr. Top. Microbiol. Immunol ... "Gastrointestinal and hepatic manifestations of tickborne diseases in the United States". Clin. Infect. Dis. 34 (9), s. 1206-12 ...
Gastrointestinal[edit]. Isotretinoin may cause non-specific gastrointestinal symptoms including nausea, diarrhea and abdominal ...
"CDC - The Emergency Response Safety and Health Database: Systemic Agent: BENZENE - NIOSH". www.cdc.gov. Archived from the ... gastrointestinal diseases (celiac disease, non-celiac gluten sensitivity, inflammatory bowel disease),[73][74][75] heart ... parental discouragement of anger may result in repression/suppression of angry feelings which manifests as gastrointestinal ...
"Antimicrobial agents for treating uncomplicated urinary tract infection in women". Cochrane Database of Systematic Reviews. 10 ... with gastrointestinal upset occurring in more than 30%.[62] Cranberry juice is thus not currently recommended for this ... Methenamine is another agent used for this purpose as in the bladder where the acidity is low it produces formaldehyde to which ... Medications that commonly cause this problem include the chemotherapeutic agent cyclophosphamide with rates of 2 to 40%.[47] ...
Ascorbic acid is a common enzymatic cofactor in mammals used in the synthesis of collagen, as well as a powerful reducing agent ... Vitamin C is generally well tolerated.[2] Large doses may cause gastrointestinal discomfort, headache, trouble sleeping, and ... Oxidized forms of the molecule such as dehydroascorbic acid are converted back to ascorbic acid by reducing agents.[3] ... Uric acid and ascorbate are both strong reducing agents. This has led to the suggestion that, in higher primates, uric acid has ...
Chemotherapy agents used to treat cholangiocarcinoma include 5-fluorouracil with leucovorin,[79] gemcitabine as a single agent, ... 21 July 2006). Sleisenger and Fordtran's Gastrointestinal and Liver Disease (8th ed.). Saunders. pp. 1493-6. ISBN 978-1-4160- ... Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH (February 2005). "Single-agent gemcitabine in the treatment of ... Journal of Gastrointestinal Cancer. 43 (2): 137-47. doi:10.1007/s12029-011-9284-y. PMID 21597894.. ...
... and gastrointestinal tract in the form of Helicobacter without causing disease in the host. They also have wide medicinal and ... and can also serve as growth promoting or biocontrol agents, or cause disease in some species of plants. Actinomycetales can be ...
"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (PDF). The Panel on Antiretroviral Therapy and ... Tamén está ligada á caída do sistema de vixilancia inmunitaria da barreira da mucosa gastrointestinal causada pola diminución ... Panel on Antiretroviral Guidelines for Adults and Adolescents (2009-12-01). Guidelines for the use of antiretroviral agents in ... Coovadia H (2004). "Antiretroviral agents-how best to protect infants from HIV and save their mothers from AIDS". N. Engl. J. ...
"Antimicrobial Agents and Chemotherapy. 55 (3): 1162-72. doi:10.1128/AAC.01402-10. PMC 3067123. PMID 21173186.. ... in the gastrointestinal tract of humans and animals,[2] but it may also be pathogenic, causing diseases such as neonatal ...
The gastrointestinal tract can be damaged following abdominal and pelvic radiotherapy.[22] Atrophy, fibrosis and vascular ... of the radioactive agents being infused.[15] Methods, techniques and devices are available to lower the occurrence of this type ... "Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy". Journal of vascular and ... These medications were the first agents of what is known as radioimmunotherapy, and they were approved for the treatment of ...
Identification of an infectious agent for a minor illness can be as simple as clinical presentation; such as gastrointestinal ... The antigen (usually a protein or carbohydrate made by an infectious agent) is bound by the antibody, allowing this type of ... Fast and relatively simple biochemical tests can be used to identify infectious agents. For bacterial identification, the use ... Using a similar basis as described above, immunoassays can detect or measure antigens from either infectious agents or the ...
"Antimicrobial Agents and Chemotherapy. 38 (8): 1864-67. doi:10.1128/aac.38.8.1864. PMC 284652. PMID 7986023.. ... In children, gastrointestinal symptoms such as vomiting, diarrhea, and abdominal pain,[21][22] (may be severe in children with ... The first influenza virus to be isolated was from poultry, when in 1901 the agent causing a disease called "fowl plague" was ... "High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents- ...
There is no evidence that donepezil or other similar agents alters the course or progression of Alzheimer's disease. Six-to- ... People with peptic ulcer disease or taking NSAIDS should use with caution because increased risk of gastrointestinal bleeding ... is a centrally acting reversible acetylcholinesterase inhibitor and structurally unrelated to other anticholinesterase agents.[ ...
5-HT3 receptor antagonists block serotonin receptors in the central nervous system and gastrointestinal tract. As such, they ... Cannabinoids are used in patients with cachexia, cytotoxic nausea, and vomiting, or who are unresponsive to other agents. These ...
... motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist antiparkinsonian agents ... Kapoor, A.K.; Raju, S.M. (2013). "7.2 Gastrointestinal Drugs". Illustrated Medical Pharmacology. JP Medical Ltd. p. 677. ISBN ... Poor gastrointestinal function, nausea and vomiting is a major problem for people with Parkinson's disease because most ... Suzanne Rose (October 2004). Gastrointestinal and Hepatobiliary Pathophysiology. Hayes Barton Press. pp. 523-. ISBN 978-1-59377 ...
This agent can eventually compromise the pathways of fatty acid, glycine, and pyruvate metabolism, and then become detectable ... Gastrointestinal symptoms have been seen primarily in this population and are usually related to increased feeding. ... The most common therapeutic agent available for SSADH deficiency is one that reduces the levels of GHB via inhibition of GABA ...
... gastrointestinal (GI) and renal organ systems. Poisoning can result from mercury vapor inhalation, mercury ingestion, mercury ... Gastrointestinal Decontaminants. Class Summary. These agents are empirically used to minimize systemic absorption of the toxin ... Chelating Agents. Class Summary. These agents are used to help remove a portion of the bodys mercury stores. They are ... Because of this agents ease of use, good efficacy, and safety, initiate treatment with DMSA if good evidence indicates that ...
Gastrointestinal Diseases Peptic UlcerPeptic ulcer is a scar that forms in the lining of the stomach, the lower esophagus, and ... Abdi İbrahims product range includes antianemic, antibacterial/antiviral, dermatology, endocrine, metabolism, gastrointestinal ...
For patients experiencing optic neuritis, mean change in visual acuity from baseline/nadir to week 24 as assessed by Sloan 2.5% low contrast visual acuity chart ...
Gastrointestinal Tract Decontaminants. Class Summary. These agents are used to minimize the absorption of ingested compound. ... Cardiovascular agents. Class Summary. These agents are used for symptomatic bradycardia and/or hypotension. Catecholamines are ... Agents with combined alpha- and beta-selective properties may be necessary to maintain blood pressure. A beta-agonist may ... Agents with combined alpha- and beta-selective properties may be necessary to maintain blood pressure. A beta-agonist may ...
Gastrointestinal Agent. Gastrointestinal drugs treat nausea, diarrhea, and ulcers. Some of these drugs are classified as ...
You are at: Home » Products » Pharmaceuticals and Biochemicals » Gastrointestinal agentsIn total 699093 number ofProductsinfo, ...
Gastrointestinal Agent. Gastrointestinal drugs treat nausea, diarrhea, and ulcers. Some of these drugs are classified as ... Continue Learning about Gastrointestinal Agent. What other medications interact with urinary anticholinergics? ...
What is Gastrointestinal agents? Meaning of Gastrointestinal agents medical term. What does Gastrointestinal agents mean? ... Looking for online definition of Gastrointestinal agents in the Medical Dictionary? Gastrointestinal agents explanation free. ... gastrointestinal tract. (redirected from Gastrointestinal agents). Also found in: Dictionary, Thesaurus, Encyclopedia. tract. [ ... Gastrointestinal agents , definition of Gastrointestinal agents by Medical dictionary https://medical-dictionary. ...
Anti-Ulcer Agents. Gastrointestinal Agents. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological Action. ... Gastric Ulcer Induced by Antiplatelet Agent Ulcer of the Gastrointestinal Tract Proton Pump Inhibitor Drug: Pantoprazole Phase ... Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft (DACAB ... Gastrointestinal Diseases. Digestive System Diseases. Stomach Diseases. Pantoprazole. Proton Pump Inhibitors. ...
So, the aim of this work is to study the effect of MLT as preventive agent of GI injury caused by NSAIDs. With this objective ... Now there are evidences of the involvement of multiple cellular pathways in the NSAIDs-mediated-gastrointestinal (GI) damage ... Therefore, we found that MLT may be a preventive agent of GI damages induced by NSAIDs. ... Study of Melatonin as Preventive Agent of Gastrointestinal Damage Induced by Sodium Diclofenac by Aroha B. Sánchez 1, Beatriz ...
Resumption of Antiplatelet Agents. The decision to resume antiplatelet therapy should also be highly individualized. In ... Gastrointestinal (GI) bleeding is a serious complication of anticoagulant and antiplatelet therapy. Risks for GI bleeding ... Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. J Clin Gastroenterol. 2009;43(1):5-12. ... Given the lack of reversing agents for these drugs, we recommend exercising caution in populations with a high risk of ...
Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal ... Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future ... 2 Approved Agents. 2.1 Imatinib. Imatinib has been considered the standard first-line agent since its approval in 2002. It is ... Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal ...
Hydrogen Sulfide: An Agent of Stability at the Microbiome-Mucosa Interface. John L Wallace, Jean-Paul Motta, Andre G Buret ... Hydrogen Sulfide: An Agent of Stability at the Microbiome-Mucosa Interface Message Subject (Your Name) has forwarded a page to ... American Journal of Physiology - Gastrointestinal and Liver Physiology Published 12 October 2017 Vol. no. , DOI: 10.1152/ajpgi. ... H2S donors can modify the gut microbiota and the gastrointestinal epithelium is a major site of oxidation of microbial-derived ...
American Journal of Physiology - Gastrointestinal and Liver Physiology Published 1 June 1999 Vol. 276 no. 6, G1408-G1416 DOI: ... 1 and Tables3-5). All three constrictor agents, i.e., ANG II, NE, and ET-1, caused a significantly greater peak level and ... Effects of sustained low-flow perfusion on the response to vasoconstrictor agents in postnatal intestine. Philip T. Nowicki ... A significant leftward shift in the dose-response curve was observed for all three constrictor agents (Fig. 3). The calculated ...
Gastrointestinal bleeding is a well-known complication of these agents. Modification of anticoagulant and antiplat ... Anticoagulants and antiplatelet agents are widely used in the prophylaxis and management of thromboembolic and cardiovascular ... Gastrointestinal bleeding is a well-known complication of these agents. Modification of anticoagulant and antiplatelet therapy ... Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal ...
Antimicrobial Agents and Chemotherapy Nov 2013, 57 (12) 6290-6294; DOI: 10.1128/AAC.01405-13 ... Antimicrobial Agents and Chemotherapy Nov 2013, 57 (12) 6290-6294; DOI: 10.1128/AAC.01405-13 ... A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse ... Thank you for sharing this Antimicrobial Agents and Chemotherapy article.. NOTE: We request your email address only to inform ...
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal ... A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal ... A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal ... A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal ...
Gastrointestinal transit was analysed in vivo prior to and following 3, 7, and 14 days of 5-FU treatment via serial x-ray ... Long-term treatment (7, 14 days) resulted in delayed gastrointestinal transit, inhibition of colonic migrating motor complexes ... KEY RESULTS Short-term administration of 5-FU (3 days) increased gastrointestinal transit, induced acute intestinal ... CONCLUSIONS & INFERENCES Our results indicate that 5-FU induces accelerated gastrointestinal transit associated with acute ...
The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell ... A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal ... Novel agents. mTOR inhibitors. Novel approaches to overcome resistance to TKIs in GIST include targeting multiple levels of the ... Based on these data, this agent was approved for treatment of GIST following failure of imatinib in January 2006.. Table 1 TKIs ...
Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers.. @ ... article{Poen1999EffectOP, title={Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal ... Pharmacologic , Pharmacokinetic , and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. *Michael Camilleri, ...
Gastrointestinal Agents Market Was Valued At US$ 17,255.3 Mn In 2016, And Is Expected To Reach US$ 21,177.7 Mn By 2025, ... 2.3 Global Gastrointestinal Agents Market Revenue, by Geography, 2016 (US$ Million). Chapter 3 Global Gastrointestinal Agents ... TABLE 8 Global Gastrointestinal Agents Market, by Region, 2015 - 2025 (US$ Mn). TABLE 9 North America Gastrointestinal Agents ... TABLE 10 Europe Gastrointestinal Agents, by Country, 2015 - 2025 (US$ Mn). TABLE 11 Asia Pacific Gastrointestinal Agents, by ...
Gastrointestinal Agents. Treat rheumatoid arthritis, Crohns Disease, or ulcerative colitis. REMICADE (infliximab) ... Sedative-Hypnotic Agents. Treat insomnia or sleeping disorders. AMBIEN (zolpidem), AMBIEN CR (zolpidem), BUTISOL (butabarbital ... Erectile Dysfunction/Impotence Agents. Treat male impotence. CIALIS (tadalafil), CAVERJECT, EDEX (alprostadil inj), LEVITRA ( ... Respiratory Agents. Treat special bronchial-related disease states. PULMOZYME (recombinant dornase alfa inhalation solution), ...
style,#search-block .headerSearchBox{border-bottom-left-radius:3px !important;border-top-left-radius:3px !important;}.show-title-for-nojs{display:none;},/style, ,div id="search-title" class="show-title-for-nojs", ,label for="headerSearchKeyword",Drug. / Keyword,/label, ,/div ...
Gastrointestinal Motility Agents. Posaconazole Delayed-Release Tablet. Concomitant administration of metoclopramide with ... 400-mg single dose with a prokinetic agent (metoclopramide 10 mg TID for 2 days) + BOOST or an antikinetic agent (loperamide 4- ... Posaconazole is an azole antifungal agent [see Microbiology].. Pharmacodynamics. Exposure Response Relationship. In clinical ... Noxafil is an azole antifungal agent available as concentrated solution to be diluted before intravenous administration, ...
Gastrointestinal Motility Agents. cisapride. HMG CoA-Reductase Inhibitors. atorvastatin, cerivastatin, lovastatin, simvastatin ... Gastrointestinal Motility Agents. Co-administration of itraconazole with cisapride can elevate plasma cisapride concentrations ... Oral Hypoglycemic Agents. Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and ... Gastrointestinal disorders:. Abdominal pain, vomiting, dyspepsia, nausea, diarrhea, constipation, dysgeusia. Hepato-biliary ...
Precautions: Gastrointestinal Agents *Avoid phosphate and Magnesium containing Laxatives or enemas. *Avoid Magnesium containing ... Agents to avoid at any level of CRF or risk of CRF. *NSAIDS (repeat Serum Creatinine q2 weeks if used) ... Agents to avoid in severe CRF (GFR ,30 ml/min) that are typically avoided for other risks (listed for historical reasons). * ... Preferred agents in CRF (renal and cardioprotective). *Starting dose. *Moderate dose in most patients (e.g. Lisinopril 10-20 mg ...
Causes: Gastrointestinal Agents *Aluminum hydroxide Antacids. * H2 Receptor Antagonists (e.g. Ranitidine) ... Gastrointestinal Opioid Antagonist Glyceryl trinitrate H2 Receptor Antagonist Hepatitis A Immunoglobulin Hepatitis B ...
Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic ...
... , Chitosan Derivatives, Chitosan Agriculture ... Chitosan in Animal Health - Gastro Intestinal Diseases, Antimicrobial agent Dietary supplementation of chitosan & chitosan ... Description : Chitosan Nanoparticles are useful as antibacterial agents. Chitosan nano particles are widely used f... ...
Natural oral contrast agents for gastrointestinal magnetic resonance imaging Assiut Univ. Bull. Environ. Res. 2015; 2 (4): 200- ... Oral contrast agents can be the artificial materials or natural factors. Natural contrast agents consist of fruit juice or ... We briefly reviewed the different types of contrast agents and focused on the studies in which natural oral contrast agents ... Some advantages have been reported regarding the natural types of contrast agents over the artificial agents including better ...
  • a radiological examination of the upper gastrointestinal tract using barium as the contrast medium for a series of x-ray films. (thefreedictionary.com)
  • Hydrogen sulfide is produced gastrointestinal tract tissues and by bacteria residing within the gut, and can influence the function of a wide range of cells. (physiology.org)
  • Evidence from animal studies suggests that chlamydiae may persist in the gastrointestinal tract (GI) and be a reservoir for reinfection of the genital tract. (asm.org)
  • Alternatively, it is possible that women become autoinfected from the gastrointestinal (GI) tract. (asm.org)
  • Thus, we have proposed that chlamydiae can persist in the gastrointestinal tract and that women can be reinfected in the genital tract by autoinfection from the rectum. (asm.org)
  • Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. (pharmacycode.com)
  • Unfortunately, these compounds are equally capable of inhibiting constitutively expressed COX-1 in tissues such as the gastrointestinal tract and kidney, which results in serious, mechanism-based toxicities that limit the drug's therapeutic utility. (wustl.edu)
  • Masferrer, JL, Isakson, PC & Seibert, K 1996, ' Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract ', Gastroenterology Clinics of North America , vol. 25, no. 2, pp. 363-372. (wustl.edu)
  • Lafutidine is a generic antihistamine drug which is used to treat diseases involving the gastrointestinal tract such as oesophagus. (tradeindia.com)
  • An Update on the Role of Immunohistochemistry in the Evaluation of Gastrointestinal Tract Disorders. (bioportfolio.com)
  • Gastrointestinal stromal tumors (GISTs) are rare, but represent the most common mesenchymal neoplasms of the gastrointestinal tract. (bioportfolio.com)
  • To evaluate the diagnostic yield of the cell block (CB) technique with immunohistochemistry in patients with mesenchymal neoplasms of the gastrointestinal tract collected by endoscopic ultrasound-guid. (bioportfolio.com)
  • It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. (bioportfolio.com)
  • Gastrointestinal and urinary tract stimulants. (worldcat.org)
  • To study the safety, tolerability, and pharmacokinetics of the selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib in patients with advanced imatinib-resistant gastrointestinal stromal tumors. (aacrjournals.org)
  • The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. (biomedcentral.com)
  • EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. (bioportfolio.com)
  • Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. (bioportfolio.com)
  • Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. (bioportfolio.com)
  • Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy -- a nation-wide survey in Germany. (biomedsearch.com)
  • A survey of the American Society for Gastrointestinal Endoscopy (ASGE), performed several years ago, showed a wide variation between endoscopists in the management of anticoagulants and antiplatelet agents in the periendoscopic period. (biomedsearch.com)
  • Periprocedural management of antithrombotics for gastrointestinal endoscopy is a common clinical issue, given the widespread use of these drugs for primary and secondary cardiovascular prevention. (annalsgastro.gr)
  • Upper gastrointestinal bleeding is the leading emergency leading to hospitalization and urgent endoscopy. (google.com)
  • TRPV4 Channel Signaling in Macrophages Promotes Gastrointestinal Motility via Direct Effects on Smooth Muscle Cells. (semanticscholar.org)
  • X-ray analysis of gastrointestinal motility in conscious mice. (semanticscholar.org)
  • Antidiarrheal agents == '''Antidiarrheal agents''' include bulk forming agents, hydroscopic agents, bile acid resins, [[bismuth]], inhibitors of intestinal motility, non-absorbed antibiotics and hormones. (wikimd.org)
  • When Should Antiplatelet Agents and Anticoagulants Be Restarted after Gastrointestinal Bleed? (the-hospitalist.org)
  • The decision to restart antiplatelet agents and/or anticoagulants should involve a patient-specific approach regarding potential risks and benefits. (the-hospitalist.org)
  • Although there is consensus on ceasing anticoagulant and antiplatelet agents during an acute GI bleed, debate remains over the appropriate approach to restarting these agents. (the-hospitalist.org)
  • Anticoagulants and antiplatelet agents are widely used in the prophylaxis and management of thromboembolic and cardiovascular diseases. (biomedsearch.com)
  • Our data demonstrate that, in spite of the dissemination of guidelines, there is still a wide variation in the periendoscopic management of patients who are at increased risk for bleeding due to anticoagulants, especially in patients taking antiplatelet agents. (biomedsearch.com)
  • Conventional chemotherapy agents have little activity against GIST. (springer.com)
  • Impact of chemotherapy on gastrointestinal functions and the enteric nervous system. (semanticscholar.org)
  • Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. (semanticscholar.org)
  • The purpose of this study is to define the recommended dose of BMS-582664 that could be safely combined with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimens in patients with advanced gastrointestinal malignancies and to evaluate the safety profile, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of these combinations. (bioportfolio.com)
  • In a preferred embodiment, said nanoparticle contains a diagnostic or therapeutic agent therein. (google.com)
  • 1. A composition comprised of nanoparticles consisting essentially of 99.9-10% by weight of an organic crystalline therapeutic or diagnostic agent having tyloxapol adsorbed on the surface thereof in an amount of 0.1-90% by weight and sufficient to maintain an average particle size of less than 400 nm. (google.com)
  • and an additional surface modifier associated therewith, said method comprising contacting said therapeutic or diagnostic agent with tyloxapol for a time and under conditions sufficient to provide a nanoparticle-tyloxapol composition. (google.com)
  • Some commonly used pesticides (for example, the organophosphate (OP) Malathion and the carbamate Sevin) and some common therapeutic drugs (the carbamates pyridostigmine [Mestinon] and physostigmine [Antilirium]) also inhibit acetylcholinesterase and can be considered 'nerve agents. (fas.org)
  • Providing both understanding and guidance in characterizing potential drugs and their production and synthesis, Development of Therapeutic Agents Handbook gives professionals a basic tool to facilitate research and development within this challenging process. (wiley.com)
  • This comprehensive text brings together, in one resource, a compendium of concepts, approaches, methodologies, and limitations that need to be considered in the formulation of therapeutic agents across a range of therapeutic fields. (wiley.com)
  • Both a reference and a call to action for the pharmaceutical industry, Development of Therapeutic Agents Handbook examines recent innovations taking shape in the various medical disciplines involved in drug discovery, and shows why these advances need to be embraced universally among researchers to improve their solution strategies. (wiley.com)
  • Development of Therapeutic Agents Handbook serves this purpose, acting as both a one-stop reference rich in valid science, and a tool to carve out new pathways in the pursuit of bringing safer and more effective drugs to the marketplace. (wiley.com)
  • Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. (nih.gov)
  • A major objective for the clinical evaluation of mAbs has been determining the toxicity and therapeutic efficacy of the antibody alone or as a delivery system for radioisotopes or other toxic agents. (nature.com)
  • Active ingredients of central nervous system agents will remain the largest therapeutic group served by pharmaceutical chemicals based on value and will post above average revenue growth. (freedoniagroup.com)
  • American Journal of Physiology - Gastrointestinal and Liver Physiology Published 12 October 2017 Vol. no. (physiology.org)
  • Thank you for your interest in spreading the word about Gastrointestinal and Liver Physiology. (physiology.org)
  • Message Body (Your Name) thought you would like to see this page from the Gastrointestinal and Liver Physiology web site. (physiology.org)
  • Regional differences in the manifestation of gastrointestinal motor disorders in type 1 diabetic pat. (biomedsearch.com)
  • Thus rise in chronic gastrointestinal disorders and diseases, along with availability of OTC drugs are driving the growth of gastrointestinal drugs market. (credenceresearch.com)
  • Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. (mendeley.com)
  • 5. Gastrointestinal agents: Agents used to treat acid peptic disorders. (worldcat.org)
  • Chlorpromazine was approved for use in the United States in 1957 and was formerly the most commonly prescribed antipsychotic medication, being the prototypic, standard neuroleptic agent against which other antipsychotic agents were tested. (nih.gov)
  • Antipsychotic agents. (worldcat.org)
  • Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. (springer.com)
  • Sunitinib and regorafenib are approved as second- and third-line agents, respectively, for patients whose GIST does not respond to imatinib or who do not tolerate imatinib, and their use is supported by large randomized trials. (springer.com)
  • Besides ATP-mimetic tyrosine kinase inhibitors many other agents with a different mechanism of action are efficacious in the treatment of patients with advanced GIST. (springer.com)
  • Concomitant or sequential administration of agents with different mechanisms of action may become a novel approach to treat advanced GIST. (springer.com)
  • We review here the experimental agents studied to treat imatinib-resistant advanced GIST. (springer.com)
  • In this review, we discuss the highlights of recent advances and novel agents for GIST therapy. (biomedcentral.com)
  • Remarkable developments have occurred in gastrointestinal stromal tumor (GIST) research and clinical care in the past several years. (biomedcentral.com)
  • As previously discussed, 2,3-dimercaptosuccinic acid (DMSA) and N -acetyl-D,L-penicillamine have been used as chelating agents in the treatment of mercury toxicity. (medscape.com)
  • Aim: The relative gastrointestinal toxicity of NSAIDs in normal clinical practice is unknown. (uab.cat)
  • Oral contraceptives, hormone therapy, some psychotropic drugs, and some cardiovascular agents have been associated with mastalgia. (aafp.org)
  • These agents are some of the most commonly taken medications and are very well tolerated, most being available both by prescription and over-the-counter. (wikimd.org)
  • Gastrointestinal medications and breastfeeding. (drugs.com)
  • Patients should be evaluated for potential interactions between antiretrovirals and concurrent medications (including over-the-counter agents). (aafp.org)
  • Overestimating the occurrence of foodborne diseases caused by unknown agents may lead us to undervalue the public health importance of these and other well-known agents. (cdc.gov)
  • H 2 S donors can modify the gut microbiota and the gastrointestinal epithelium is a major site of oxidation of microbial-derived H 2 S. When administered together with nonsteroidal anti-inflammatory drugs, H 2 S can prevent some of the dysbiosis those drugs induce, possibly contributing to the observed prevention of gastrointestinal damage. (physiology.org)
  • These agents prevent seizure recurrence and terminate clinical and electrical seizure activity. (medscape.com)
  • Agents that have been found promising in preclinical models and early clinical trials include small molecule KIT and PDGFRA mutation-specific inhibitors, heat shock protein inhibitors, histone deacetylase inhibitors, allosteric KIT inhibitors, KIT and PDGFRA signaling pathway inhibitors, and immunological approaches including antibody-drug conjugates. (springer.com)
  • Nilotinib alone or in combination with imatinib was well tolerated overall and showed clinical activity in imatinib-resistant gastrointestinal stromal tumor patients. (aacrjournals.org)
  • The clinical effects from nerve agent exposure are caused by excess acetylcholine. (fas.org)
  • Note: The actual clinical manifestations of an exposure to a nerve agent or an organophosphate pesticide may be more variable than the syndrome described in this document. (cdc.gov)
  • The risk was significantly increased in patients with a history of peptic ulcer and/or upper gastrointestinal bleeding, and in those taking antiplatelet drugs. (uab.cat)
  • 7. Hormones and agents affecting hormonal mechanisms: Adrenal corticosteroids. (worldcat.org)
  • Now there are evidences of the involvement of multiple cellular pathways in the NSAIDs-mediated-gastrointestinal (GI) damage related to enterocyte redox state. (mdpi.com)
  • So, the aim of this work is to study the effect of MLT as preventive agent of GI injury caused by NSAIDs. (mdpi.com)
  • Therefore, we found that MLT may be a preventive agent of GI damages induced by NSAIDs. (mdpi.com)
  • The aim of this study was to estimate the risk of upper gastrointestinal bleeding associated with NSAIDs and analgesics, with special emphasis on those agents that have been introduced in recent years. (uab.cat)
  • NSAIDs are potent anti-inflammatory and analgesic agents. (wustl.edu)
  • A phase I intercohort dose-escalation trial was done in patients who received either ( a ) single agent nilotinib 400 mg twice daily or ( b ) escalating doses of nilotinib (200 mg once daily, 400 mg qd, or 400 mg bid) plus imatinib 400 mg bid (10- and 14-hour interval daily), or ( c ) nilotinib 400 mg bid plus imatinib 400 mg qd. (aacrjournals.org)
  • Conversely, bridging therapy is usually not needed for patients taking new oral agents, which are characterized by shorter half-lives, and a rapid offset and onset of action. (annalsgastro.gr)
  • In the present article we review publications reporting on phase 2 and phase 3 studies evaluating agents to potentially be used in the treatment of patients with IBS. (mendeley.com)
  • In kidney, liver, and heart transplant patients, cyclosporine [MODIFIED] may be administered with other immunosuppressive agents. (nih.gov)
  • Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking cyclosporine [MODIFIED]. (nih.gov)
  • The epidemiology is changing with more complex older patients on anticoagulant and antithrombotic agents presenting with upper gastrointestinal bleeding. (google.com)
  • In order to give optimal care to patients, it is critical that practicing gastroenterologists are aware of the many recent advances in management of patients with upper gastrointestinal bleeding. (google.com)
  • Prezista is specifically indicated for the treatment of HIV-1 infections in combination with ritonavir and other antiviral agents in treatment-experienced patients, including patients who have failed prior courses of treatment with other PIs. (centerwatch.com)
  • Gastrointestinal (GI) bleeding is a serious complication of anticoagulant and antiplatelet therapy. (the-hospitalist.org)
  • For cases where the short-term benefit of anticoagulant or antiplatelet therapy outweighs the immediate risk, the appropriate agent can be restarted within four to five days of achieving hemostasis. (the-hospitalist.org)
  • Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection. (gilead.com)
  • The attachment of the agent to the enzyme is permanent (unless removed by therapy). (fas.org)
  • However, while the OP pesticides cause the same biological effects as nerve agents, there are some important differences in the duration of biological activity and response to therapy. (fas.org)
  • Home » Products » Pharmaceuticals and Biochemicals » Gastrointestinal agents In total 717051 number ofProductsinfo,Released today. (freedomlist.com)
  • This phase I trial identified single-agent nilotinib 400 mg bid or combined with imatinib 400 mg qd as possible phase II doses for further evaluation. (aacrjournals.org)
  • For example, inhalation of a nerve agent or an OP pesticide leads to a quicker onset of poisoning with more severe symptoms when compared to with dermal exposure s, given the same amount of agent. (cdc.gov)
  • The report titled "Gastrointestinal Agents Market - Growth, Future Prospects and Competitive Analysis, 2017-2025" offers strategic insights into the overall gastrointestinal agents market along with the market size and estimates for the duration 2015 to 2025. (credenceresearch.com)
  • They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (nih.gov)
  • Led by active ingredients of anticancer, antidiabetic, and hormone replacement formulations, hormones and related agents will post the fastest growth in value among all pharmaceutical chemicals. (freedoniagroup.com)
  • Gastrointestinal drugs treat nausea, diarrhea, and ulcers. (sharecare.com)
  • After a nerve agent inhibits the tissue enzyme, the enzyme cannot hydrolyze acetylcholine, the neurotransmitter at cholinergic receptor sites. (fas.org)
  • Gastrointestinal-May cause or worsen pre-existing constipation. (webmd.com)
  • Diarrhea/constipation A. ETIOLOGIC AGENT 5. (slideshare.net)
  • Most antidiarrheal agents are active locally in the small intestine and colon and are largely not absorbed. (wikimd.org)
  • Fewer data exist with regard to the use of these agents around the time of endoscopic procedures. (biomedsearch.com)
  • Noxafil is an azole antifungal agent available as concentrated solution to be diluted before intravenous administration, delayed-release tablet, or suspension for oral administration. (rxlist.com)
  • ONMEL (itraconazole) is a synthetic triazole antifungal agent for oral use. (rxlist.com)
  • Antifungal agents. (worldcat.org)
  • SPORANOX® is the brand name for itraconazole, a synthetic triazole antifungal agent. (globalrph.com)
  • These agents help in relieving gastrointestinal acid reflux. (medscape.com)
  • 6. Cardiac, vascular, and renal agents: Agents used to treat migraine. (worldcat.org)
  • The likely presenting symptoms would be _ because most infectious agents are distributed in _ form, but _ outbreaks through _ could also occur. (brainscape.com)
  • The following is a more comprehensive list of signs and symptoms that may be encountered in a person exposed to a nerve agent or OP pesticide. (cdc.gov)
  • In this study scope, gastrointestinal disease or disorder includes gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). (credenceresearch.com)
  • Even though "accurate estimates of disease burden are the foundation of sound public health policy" (2) , most of these estimates (in particular, the assumption that unknown agents are transmitted by food in the same proportion as known agents) were derived from assumptions rather than data. (cdc.gov)
  • If eradicating Campylobacter , Salmonella, Escherichia coli O157:H7, and Listeria would reduce the number of foodborne illnesses by only 5%, hospitalizations by 10%, and deaths by 25%, why are these agents the primary focus of our national foodborne disease control efforts? (cdc.gov)
  • Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. (semanticscholar.org)
  • Although most useful if administered within 4 hours of ingestion, repeated doses may be used, especially with ingestions of sustained-released agents. (medscape.com)